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The stromal microenvironment has key roles in prostate
development and cancer, and cancer-associated ﬁbroblasts
(CAFs) stimulate tumourigenesis via several mechanisms
including the expression of pro-tumourigenic factors.
Mesenchyme (embryonic stroma) controls prostate orga-
nogenesis, and in some circumstances can re-differentiate
prostate tumours. We have applied next-generation
Tag proﬁling to fetal human prostate, normal human
prostate ﬁbroblasts (NPFs) and CAFs to identify
molecules expressed in prostatic stroma. Comparison
of gene expression proﬁles of a patient-matched pair of
NPFs vs CAFs identiﬁed 671 transcripts that were
enriched in CAFs and 356 transcripts whose levels were
decreased, relative to NPFs. Gene ontology analysis
revealed that CAF-enriched transcripts were associated
with prostate morphogenesis and CAF-depleted tran-
scripts were associated with cell cycle. We selected
mRNAs to follow-up by comparison of our data sets with
published prostate cancer ﬁbroblast microarray proﬁles as
well as by focusing on transcripts encoding secreted and
peripheral membrane proteins, as well as mesenchymal
transcripts identiﬁed in a previous study from our group.
We conﬁrmed differential transcript expression between
CAFs and NPFs using QrtPCR, and deﬁned protein
localization using immunohistochemistry in fetal prostate,
adult prostate and prostate cancer. We demonstrated that
ASPN, CAV1, CFH, CTSK, DCN, FBLN1, FHL1,
FN, NKTR, OGN, PARVA, S100A6, SPARC, STC1
and ZEB1 proteins showed speciﬁc and varied expression
patterns in fetal human prostate and in prostate cancer.
Colocalization studies suggested that some stromally
expressed molecules were also expressed in subsets of
tumour epithelia, indicating that they may be novel
markers of EMT. Additionally, two molecules (ASPN
and STC1) marked overlapping and distinct subregions
of stroma associated with tumour epithelia and may
represent new CAF markers.
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Introduction
Prostate cancer is the most prevalent cancer in UK men,
with around 36000 new cases and B10000 deaths per
year. The role of the tumour microenvironment in
prostate cancer initiation and progression is important,
but is poorly understood at the mechanistic or molecular
level. Tumour stroma (cancer-associated ﬁbroblasts,
CAFs) stimulates prostate carcinogenesis (Olumi et al.,
1999; Hayward et al., 2001) and stromal histology is an
independent predictor of prostate cancer prognosis
(Ayala et al., 2003; Yanagisawa et al., 2007). There is
considerable interest in identifying pathways in tumour
stroma that act as paracrine regulators of tumour
epithelia, as these may become new therapeutics or
diagnostics and would be a novel intervention in tumour
growth. The study of stromal involvement in breast
cancer has identiﬁed several functions in tumour
progression and metastasis. Serial analysis of gene
expression (SAGE) proﬁling of breast cancer stroma
identiﬁed SDF1/CXCL12 (Allinen et al., 2004), which
was subsequently shown to stimulate epithelial prolif-
eration as well as recruitment of endothelial precursors
from bone marrow (Orimo et al., 2005). Stromal gene
expression pattern predicts disease progression (Finak
et al., 2008; Ma et al., 2009), while signalling from
mesenchymal stem cells via CCL5 stimulates metastasis
(Karnoub et al., 2007). In the prostate, stromal
signalling may initiate some tumours (Bhowmick
et al., 2004; Placencio et al., 2008), stimulate tumour
cell proliferation (Olumi et al., 1999; Hayward et al.,
2001), enhance vasculogenesis (Tuxhorn et al., 2002)
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CXCL12 and CXCL14 have been identiﬁed as pro-
tumourigenic mediators made by prostate tumour
stroma (Ao et al., 2007; Augsten et al., 2009).
The developing prostate shares some characteristics
with prostate tumours, including rapid growth driven by
paracrine interactions from the mesenchyme/stroma
(Hayward et al., 1996). Embryonic mesenchyme has
been shown to inhibit tumour growth in the Dunning
tumour model system (Hayashi and Cunha, 1991),
which illustrates the potency of mesenchymal paracrine
pathways. Additionally, proﬁling of developmental
mesenchyme has identiﬁed pathways that are dysregu-
lated in CAFs (Vanpoucke et al., 2007), and other
studies have demonstrated similarities between develop-
mental gene expression and prostate tumours (Joesting
et al., 2005; Schaeffer et al., 2008; Pritchard et al., 2009).
CAFs are deﬁned by their pro-tumourigenic signalling
to epithelia, and assayed by tumour reconstitution
studies in vivo and there appears to be signiﬁcant
cellular heterogeneity within CAFs (Sugimoto et al.,
2006). Recent studies have demonstrated that the
heterogeneity of tumour stroma and CAFs is a key
feature of their pro-tumourigenic activity (Franco et al.,
2011; Kiskowski et al., 2011). Gene proﬁling studies
have examined the transcriptional proﬁle of cancer
stroma and stromal subsets (Zhao et al., 2007; Dakhova
et al., 2009; Pascal et al., 2009) to identify CAF
upregulated and downregulated molecules. The cellular
heterogeneity of CAFs is a potential problem in gene
proﬁling studies, since there may be a sub-population of
cells that express key paracrine factors that are present
as a minority among a complex mix of other cells.
In regard to developmental studies, restricted subsets of
prostatic mesenchyme are known to contain organ-
inductive activity as well as localized expression of key
regulatory molecules (Timms et al., 1995; Thomson and
Cunha, 1999). By comparing transcriptional proﬁles of
embryonic mesenchyme and CAFs, it may be possible to
identify molecules expressed in cell subsets that would
be poorly represented due to their dilution by transcripts
from other cell types, as well molecules that are co-
expressed due to the similarity of cellular events in
development and disease. Furthermore, few molecules
have been identiﬁed whose expression is restricted to
the stromal compartment, and such molecules may
be important as CAF markers or regulatory factors. In
addition, the identiﬁcation of stromal-speciﬁc molecules
is a prerequisite for the identiﬁcation of epithelial-
mesenchymal transition (EMT) markers.
We have examined the transcripts expressed in CAF,
normal human prostate ﬁbroblast (NPF) and fetal
prostate using Tag proﬁling, and compared our data
set with published studies of prostate cancer stroma.
This led to the identiﬁcation of several putative
stromally expressed transcripts, and expression was
examined by QrtPCR in several matched CAF/NPF
pairs and fetal prostate. The distribution of 15 candidate
proteins was examined by immunohistochemistry in
fetal human prostate, benign prostate and prostate
cancer samples to verify stromal expression and
to look for expression in stromal subsets or epithelia.
Four molecules were further studied using confocal
colocalization, to determine their co-expression in
epithelia or stromal subsets. We identiﬁed several
molecules expressed in developing human prostate
mesenchyme and CAFs, whose expression was restricted
to the stromal compartment, and our data are consistent
with the paradigm that cancer and developmental
systems share several pathways.
Results
Tag proﬁling of fetal human prostate, primary adult
normal and cancer-associated prostate ﬁbroblast cells
To identify transcripts expressed in normal and cancer
prostate stroma and developing prostate, we performed
Tag proﬁling of primary human normal and cancer-
associated prostatic ﬁbroblast cells (from the same
patient) and human fetal (14–15 weeks) prostate. The
gene expression proﬁles that we obtained by tag proﬁling
yielded 2.4–3.6 million signature sequences (Tags) per
data set for the NPF, CAF and fetal (embryonic, EMB)
samples (available at GEO GSE25018). Each tag library
was ﬁltered to include only well-annotated tags (assigned
class 1, 2 or 3 according to their relationship to the
polyA tail). Next, the tag libraries were ﬁltered to include
tags with transcripts per million (TPM) X3, which
represents B1 transcript per cell, and eliminates
extremely low frequency Tags. An overview of the
composition of the CAF, NPF and EMB tag libraries is
presented in Table 1.
To identify shared and unique tag expression in the
NPF, CAF and EMB data sets, the libraries were
compared by the tag/signature sequences using Micro-
soft Access software. Distinct and overlapping tag
expression in the NPF, CAF and EMB libraries were
determined, and are presented in a Venn diagram
(Figure 1a). The numbers in the Venn diagram refer to
tag number and not unique transcript expression
(unigene ID) since there may be more than one tag
type per gene due to splice variants. The number
of unique tags in the EMB library was greater than
the CAF and NPF libraries. The EMB tag library is
derived from a complex tissue made up of several cell
types (epithelial, ﬁbroblast, neuroendocrine, endothelial
and immune cells) present in the developing prostate.
The CAF and NPF libraries were made from primary
cultures of ﬁbroblasts, which are likely heterogeneous
populations of ﬁbroblast subgroups. Comparison of
Table 1 An overview of the Tag libraries for CAF, NPF and EMB
samples
Total tags Class 1, 2, 3 tags Unigene entries
CAF 2456219 1731530 16155
NPF 2458891 1773373 14730
EMB 3648190 2456190 20460
Abbreviations: CAF, cancer-associated ﬁbroblast; EMB, embryonic
prostate; NPF, normal human prostate ﬁbroblast.
Tag proﬁling prostate to identify stromal molecules
BO r ret al
1131
Oncogenethe three tag libraries demonstrated that the CAF and
EMB libraries shared a greater number of tags with
unique UGID (1404 tags; 1342 UGIDs) than the CAF
and NPF (851 tags; 777 UGIDs) or the NPF and
EMB proﬁles (1064 tags; 1054 UGIDs). Tags identiﬁed
as unique or shared between libraries are listed in
Supplementary File 1.
Identiﬁcation of CAF-enriched or -depleted transcripts
and comparison with reactive stroma and CD90þve
CAFs
CAFs are involved in regulation of tumourigenesis,
and to determine signiﬁcant changes in tag levels we
performed statistical analysis using JumpStart software.
CAF and NPF tag lists (cl123) were compared and fold
differences calculated (after zeros were converted to
ones) followed by statistical evaluation. We identiﬁed
671 tags (500 with a gene symbol) as increased (Po0.05)
and 356 tags (281 with a gene symbol) as decreased in
C A F sv sN P F s( Po0.05). We identiﬁed three genes that
were present as both up and down in CAFs (ALDH7A1,
LYRM2 and MRCL3), due to tag splice variants.
To establish that our samples showed previously
identiﬁed markers associated with CAFs, we interro-
gated the lists for genes previously studied in prostate
cancer stroma. We identiﬁed CXCL12, HIF1a, GFRa1,
ERa, Hes1 and FIGF (VEGFD) as enriched in CAFs
(Allinen et al., 2004; Orimo et al., 2005) and PHB,
WFDC1 and CALD as depleted in CAFs (Franco et al.,
2011; Kiskowski et al., 2011). Tags with a gene symbol
were carried forward for comparison with published
microarray data of prostate stroma.
CD90 was reported as enriched in prostate cancer
stroma was used for microarray analysis of CD90þve
isolated prostate tumour stromal cells (CD90þve cells vs
CD49aþve cells, normal ﬁbroblasts; Pascal et al.,2 0 0 9 ) .
In addition, Dakhova et al. (2009) have reported a
microarray gene proﬁle of reactive prostate stroma (grade
3) associated with prostate cancer progression and
reduced biochemical recurrence-free survival. We com-
pared transcripts enriched or depleted in CAFs with
CD90þve cells and reactive stroma (enriched and
depleted). To facilitate comparison of microarray and
tag proﬁles, we compared the data by gene symbol using
MS Access. The unique and shared gene expression
results are illustrated in Venn diagrams (Figures 1b and
c). We identiﬁed 57 enriched and 29 depleted transcripts
common to CAFs, reactive stroma and CD90þve
stromal cells and their identities are listed in Supplemen-
tary File 2. ASPN was identiﬁed as CAF enriched and co-
expressed in CD90þve stromal cells and reactive stroma,
while NKTR was identiﬁed as CAF depleted and
decreased in CD90þve stromal cells and reactive stroma.
Gene Ontology analysis of gene expression data
To identify key processes in CAFs, we used GeneGO
software to perform functional classiﬁcation of well-
annotated transcripts with a gene symbol: (1) expressed
in both CAF and EMB libraries; (2) enriched/depleted
in CAFs vs NPFs; and (3) enriched/depleted in
CAFs vs reactive stroma or CD90þve stromal cells.
Figure 1 Overlapping and speciﬁc Tag expression between CAF,
NPF and fetal (EMB) human prostate, and comparison with other
data sets. (a) A Venn diagram illustrates the overlap of tags
between CAF, NPF and EMB libraries. In all, 12256 tags were
co-expressed between all three libraries, and these comprise
ubiquitous or broadly expressed transcripts. The greatest number
of co-expressed tags was between CAF and EMB libraries (1404),
while the least co-expressed tags were between CAF and NPF
(851); NPF and EMB co-expressed 1064 tags. The EMB library
contained the highest number of unique tags (19449) as well as
speciﬁc tags (4725), which is most likely due to the complex cellular
composition of the fetal prostate in comparison with CAF and
NPF primary cells. Tag library details are given in Table 1 and Tag
lists are in Supplementary File 1. Comparison of the CAF with
NPF sample identiﬁed CAF-enriched and CAF-depleted Tags. In
all, 500 tags with gene symbols were identiﬁed as enriched (up) in
CAF vs NPF, while 281 tags with gene symbols were depleted
(down) in CAF vs NPF. These are listed in Supplementary File 2,
and were compared with existing data sets (below). (b) Comparison
of CAF-enriched (up) or -depleted (down) transcripts with those
identiﬁed in CD90þve stromal cells. Pascal et al. (2009) identiﬁed
7379 transcripts enriched in CD90þve stromal cells and 199
(of 500 CAF enriched) were co-expressed in our data set, while
6298 transcripts were decreased in CD90þve cells and 105 (of 281
CAF depleted) were co-expressed with our data set. (c) Compar-
ison of CAF-enriched (up) or -depleted (down) transcripts with
those identiﬁed in reactive stroma. Dakhova et al. (2009) identiﬁed
4969 transcripts enriched in reactive stroma and 135 (of 500) CAF-
enriched tags were co-expressed in our data set, while 5449
transcripts were decreased in reactive stroma and 94 (of 281) CAF-
depleted tags were co-expressed with our data set. Approximately
30–40% of the CAF-enriched or -depleted transcripts were present
in either CD90þve stromal cells or reactive stroma. Fifty-seven
transcripts were identiﬁed as enriched in CAFs and co-expressed
in both CD90þve stromal cells and reactive stroma, while
29 transcripts were depleted in CAFs and co-expressed in both
CD90þve stromal cells and reactive stroma (Supplementary
File 2). Of note, ASPN was identiﬁed as CAF enriched and
co-expressed in CD90þve stromal cells and reactive stroma, while
NKTR was identiﬁed as CAF depleted and decreased in CD90þve
stromal cells and reactive stroma.
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OncogeneGene symbols or Unigene ID was used as gene
identiﬁers. The top 10 enriched process networks
and pathway maps are listed in Figure 2 and Supple-
mentary File 3. This analysis co-identiﬁed ASPN,
FBLN1, FN and OGN as among the top CAF-enriched
molecules.
Selection of candidates for further analysis
We applied several criteria to the selection of candidate
molecules for further analysis, which included the
following.
We selected secreted and peripheral membrane
molecules from the CAF-enriched/depleted molecules
CAF Enriched CAF Depleted
Processes Networks Processes Networks
prostate epithelial cord
arborization involved in
prostate glandular
acinus morphogenesis
Cell adhesion_Amyloid 
proteins
mitotic cell cycle Cytoskeleton_Spindle 
microtubules
prostate glandular 
acinus morphogenesis
Cell cycle_G2-M cell cycle phase Cell cycle_Mitosis
branching involved in 
prostate gland 
morphogenesis
Signal 
transduction_ESR1-
nuclear pathway
mitosis Cell cycle_Core
prostate gland growth Proteolysis_Ubiquitin -
proteasomal proteolysis
nuclear division Cell cycle_S phase
positive regulation of 
retinoic acid receptor 
signaling pathway
Protein folding_Protein 
folding nucleus
M phase of mitotic cell 
cycle
Cell cycle_G2-M
uterus development Transcription_Nuclear 
receptors 
transcriptional 
regulation
organelle fission Cell adhesion_Platelet-
endothelium-leucocyte 
interactions
prostate epithelial cord 
elongation
Development_Skeletal 
muscle development
M phase Inflammation_Interferon 
signaling
prostate gland 
morphogenetic growth
Signal 
Transduction_TGF-
beta, GDF and Activin 
signaling
cell division Immune_Th17-derived 
cytokines
antral ovarian follicle 
growth
Signal 
transduction_CREM 
pathway
cell cycle process DNA 
damage_Checkpoint
vagina development Reproduction_FSH-
beta signaling pathway
cell cycle Immune_Innate 
immune response to 
RNA viral infection
Top network CAF enriched Top network CAF depleted
Figure 2 Gene Ontology analysis of enriched and depleted processes and networks in CAFs vs NPFs. GeneGo software was used to
compare transcripts identiﬁed in CAF with NPF. CAF-enriched processes were predominantly those involved in prostate development,
but also included those involved in other reproductive organ growth such as uterus, oocyte and vagina. The processes most depleted in
CAFs were associated with cell cycle, suggesting a lower proliferative rate in CAFs. Gene Ontology analysis was also applied
to molecules enriched or depleted in CAFs and co-expressed in CD90þve stromal cells and reactive stroma (Supplementary File 3).
The top networks enriched in CAFs included ASPN, FBLN1, FN and OGN.
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Oncogene(Po0.05) using GeneALaCarte (http://www.genecards.
org/).
We selected stromal candidates that showed over-
lapping gene expression in CAFs vs NPFs (Po0.05) and
reactive stroma (Dakhova et al., 2009) and/or
CD90þve stromal cells (Pascal et al., 2009). These
were further compared with other gene expression
data on prostate stroma and prostate cancer stroma
(Madar et al., 2009; Gregg et al., 2010).
Developmental and cancer stroma expressed candi-
dates were identiﬁed by comparing gene expression in
the CAF and EMB tag proﬁles and further comparison
with developmental prostate mesenchyme (ventral me-
senchymal pad, VMP) (Vanpoucke et al., 2007).
Our selected stromal candidates were ﬁltered to
identify extracellular protein distribution and stromal
localization using the Human Protein Atlas website
(http://www.proteinatlas.org/). The analysis identiﬁed
15 molecules, 7 that were enriched in CAFs (ASPN,
CTSK, FBLN1, FN1, OGN, PARVA and ZEB1) and 5
that were depleted in CAFs (CAV1, CFH, NKTR,
S100A6 and STC1) (Table 2). In addition to these
12 molecules, DCN, FHL1 and SPARC were selected
from our previous studies of developmental prostatic
mesenchyme (Vanpoucke et al., 2007). Table 2 lists the
Tag counts of the candidate molecules in the CAF, NPF
and EMB libraries, as well as in our previous serial
analysis of gene expression (SAGE) proﬁling of
prostatic mesenchyme. This provided a comparison of
transcript abundance between adult prostate stroma and
developing prostate mesenchyme, as well as between
human and rat prostate. Furthermore, co-identiﬁcation
in both sets of libraries (Tag and serial analysis of gene
expression) provided support for stromal expression.
QrtPCR validation of selected mRNAs in CAF and
NPF patient-matched samples
To validate mRNA expression of the 15 identiﬁed
candidate molecules in CAFs and to examine whether
transcripts were consistently differentially expressed
between CAFs and NPFs, QrtPCR was performed on
the samples used for Tag proﬁling plus six additional
patient-matched pairs of CAF/NPFs (Figure 3). Human
fetal prostate (15–18 weeks) was also included in the
analysis to establish mRNA expression levels in devel-
opment. The CAF/NPFs were functionally tested using
previously described methods; CAFs produced tumours
when recombined with an epithelial cell line, whereas
NPF samples did not (data not shown) (Olumi et al.,
1999). In each case, the increase/decrease (Po0.05) of
transcript level measured by qrtPCR conﬁrmed the Tag
proﬁling results. QrtPCR analysis of additional CAF/
NPF samples showed some variability in candidate gene
expression across the sample pairs, which indicates the
heterogeneity inherent in patient CAF samples due to
variable patient progression and outcome. CXCL12 was
increased in 5 of 7 of the CAF samples, consistent
with our previous results with prostate CAFs (Ao et al.,
2007), and similar to ﬁndings in breast cancer stroma
(Allinen et al., 2004; Orimo et al., 2005). WFDC1 was
decreased in 7 of 7 of the CAF samples, as previously
reported (Watson et al., 2004; Supplementary Figure 1).
In general, of the Tag identiﬁed enriched molecules,
CTSK, FN and OGN showed the most consistent
pattern of CAF enrichment in CAFs (of the seven
selected). For the CAF-depleted molecules, CAV1
S100A6 and STC1 showed the most consistent reduction
in CAFs (of the ﬁve selected). Taken together, the
QrtPCR analysis determined that our candidates were
expressed in all of the seven CAF lines examined;
however, there appeared to be signiﬁcant variability
in patterns of increased or decreased expression levels
reﬂecting inter-patient differences in rate of disease
progression. This may reﬂect the observation that there
are multiple independent mechanisms and pathways
involved in CAF pro-tumourigenic signalling, and the
role of cellular heterogeneity in CAF function (Franco
et al., 2011; Kiskowski et al., 2011).
Expression of identiﬁed candidate proteins in fetal human
prostate
To examine the tissue and cellular distribution of our
identiﬁed candidate molecules in fetal human prostate
Table 2 Tag count (TPM) comparison of identiﬁed candidate
transcripts in CAF, NPF and EMB libraries
CAF  NPF  EMB   VMP VSU 
Gene
ASPN 2 2 2 2   1 6 2 1 4 7 
CTSK 4 5 7 1 0 0 4 7 5 3 9 8 
FBLN1  6 9 8 3 5 6 1 3 7 1 7 7 
FN1  1 1  2 6 2  2 3 6 
OGN  6  1487   12   29  
PARVA  0 4  5 0  4 4 
ZEB1  0 8  1 5 0  1 3 3 
CAV1  1 6 0 8 6  3 6 2  2 5 1 
CFH 4 0  1 2 0 
NKTR  5 2 0 0 
S100A6 7 0  1 2 4  2 5 1 
STC1 
41
2680
2037
16
149
3
10
31
0
0
0
9 66  65  12  29  
         
DCN 2319  1551  1078   4962  4143 
FHL1 181  237  619  287  133  
SPARC 1655  2712  3545  3362   2786  
Abbreviations: CAF, cancer-associated ﬁbroblast; EMB, embryonic
prostate; NPF, normal human prostate ﬁbroblast; TPM, transcripts
per million; VMP, ventral mesenchymal pad; VSU, ventral mesench-
ymal pad, smooth muscle and urethra.
Tag counts of selected candidate molecules are shown in CAF, NPF
and EMB libraries as well as previous SAGE data of developmental rat
prostate precursor (VSU) and pure inductive mesenchyme (ventral
mesenchymal pad, VMP). The tag counts shown are those statistically
compared to identify differentially expressed Tags and are calculated as
TPM (to normalize library size between the Tag and serial analysis of
gene expression techniques). Transcripts shaded in red were enriched
(up) in CAF compared with NPF, while transcripts shaded in green
were depleted (down) in CAFs compared with NPFs. The three
unshaded transcripts were identiﬁed in our previous SAGE proﬁling
studies of prostatic mesenchyme, and were determined to be secreted/
surface bound proteins. Some tags, for example, FN, PARVA and
S100A6 are tags that are likely derived from minor splice variants, since
the tag number represents a small fraction of the total tag number for
that particular transcript. Other tags, for example, ZEB1 and NKTR
are also splice variants, where the total tag count for the gene is not
statistically different. For ASPN, CTSK, OGN and STC1 the tag
counts shown are the total tags observed for these transcripts (these
differences are the most robust), while FBLN1, CAV1 and CFH have
additional tags but which also show a signiﬁcant difference. Most of the
selected candidates were expressed in both fetal human prostate (EMB)
and rat prostatic mesenchyme (ventral mesenchymal pad, VMP).
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Oncogene(18 weeks, n¼3), we performed immunohistochemistry
(Figure 4). Negative control immunohistochemistry is
shown in Supplementary Figure 6. Expression of ASPN,
FBLN, PARVA, ZEB1, CAV1, CFH, NKTR and
STC1 was observed in a subset of mesenchyme at the
outer periphery of the organ. Expression of CTSK and
S100A6 was highly restricted to a small subset of cells in
the mesenchyme, while OGN was broadly expressed
throughout the mesenchyme. CAV1, CTSK, FN, OGN,
S100A6 and ZEB1 were localized to the mesenchyme
only. The remaining candidates ASPN, CFH, FBLN1,
NKTR, PARVA and STC1 exhibited some expression
or association with epithelial ducts in addition to their
mesenchymal localization. ASPN, SPARC and STC1
are secreted molecules; and therefore, their expression/
association with the epithelium may be the result of
their secretion from the mesenchyme and binding to
the epithelium. Immunolocalization of smooth muscle
a-actin (SMACT), myosin (MYO) and E-cadherin (ECAD)
were used to identify the mesenchymal and epithelial cell
compartments (Supplementary Figure 2). DCN exhibited
a localization to mesenchyme in the centre of the fetal
prostate, with a peri-urethral distribution, while FHL1
localized to a subset of mesenchyme and smooth muscle,
and SPARC showed mesenchymal and epithelial expression
(Supplementary Figure 2).
High-power images conﬁrmed the mesenchyme-spe-
ciﬁc staining for CTSK, FBLN, FN, OGN, PARVA,
CAV1, STC1, DCN and FHL1. There was some
evidence of nuclear staining in epithelia for ASPN,
while ZEB1, CFH, NKTR, STC1 and SPARC showed
limited expression in a subset of epithelia (Figure 4;
Supplementary Figure 2).
Expression of identiﬁed candidate proteins in benign
prostate
To determine the immunolocalization of the candidate
proteins in benign prostate, we used sections from
Figure 3 QrtPCR validation of selected mRNAs in CAF and
NPF patient-matched samples and in fetal prostate. QrtPCR
for candidate mRNAs was performed on the CAF and NPF
samples used for Tag proﬁling (labelled CAF1), as well as six
further matched pairs of functionally tested CAFs and NPFs
(labelled 2–7). In all candidates, the Tag count data matched the
QrtPCR transcript level and conﬁrmed enrichment or depletion
of candidate transcripts in the CAF/NPF sample used for Tag
proﬁling. Of the CAF-enriched molecules: ASPN was increased in
two and decreased in three CAF/NPF pairs, CTSK was increased
in three CAF/NPF pairs, FBLN1 was increased in three and
decreased in two CAF/NPF pairs, FN was increased in ﬁve
CAF/NPF pairs, OGN was increased in ﬁve and decreased in one
CAF/NPF pairs, PARVA was increased in two and decreased in
four CAF/NPF pairs, ZEB1 was increased in one and decreased in
two CAF/NPF pairs. Of the CAF-depleted molecules: CAV1 was
decreased in four CAF/NPF pairs, CFH was increased in three and
decreased in four CAF/NPF pairs, NKTR was increased in three
and decreased in three CAF/NPF pairs, S100A6 was increased in
two and decreased in ﬁve CAF/NPF pairs, STC1 was increased
in one and decreased in four CAF/NPF pairs. As controls,
CXCL12 was increased in ﬁve and decreased in two CAF/NPF
pairs, while WDFC1 was decreased in seven CAF/NPF pairs
(Supplementary Figure 1; Supplementary Table 1). In addition,
transcript levels were measured in fetal human prostate (EMB) to
determine relative mRNA levels, and there was good (but not
complete) correlation with candidate Tag counts in the EMB
library (Table 2).
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Oncogenepatient transurethral resection of the prostates (n¼3).
Figure 5 shows representative areas of benign prostate
determined by their tissue histology and immunoloca-
lization of microseminoprotein, beta (MSMB) (Whi-
taker et al., 2010; Supplementary Figure 5). In areas
with normal prostate glands, most of the candidate
molecules (CTSK, FBLN1, FN, OGN, PARVA, ZEB1,
CAV1, CFH, S100A6 DCN and FHL1) were localized
to the stroma only. ASPN, NKTR and SPARC showed
some expression/association with ductal epithelia (Fig-
ure 5; Supplementary Figure 3). ASPN and STC1 were
low or absent from stroma adjacent to benign glands.
NKTR is a peripheral membrane protein, while ASPN
and SPARC are secreted proteins; therefore, the
epithelial staining associated with ASPN and SPARC
may be due to stromally expressed protein binding to
sites upon epithelial cells. The nuclear epithelial staining
observed for ASPN was unexpected, but may represent
a novel function for this protein.
Expression of identiﬁed candidate proteins in prostate
cancer
Most candidate molecules showed stromal-speciﬁc
staining in prostate cancer, and a few showed localized
regions of more intense staining. ASPN, PARVA,
S100A6 and STC1 showed strong staining in stromal
subsets, while CTSK, FN, OGN, ZEB1, CAV1, CFH,
DCN, FHL1 and SPARC showed expression through-
out the stroma, and FBLN and NKTR showed
expression in few cells dispersed through the stroma
(Figure 6; Supplementary Figure 4). Comparison of
candidate expression patterns between benign (Figure 5)
and cancer (Figure 6) supported the increase in
transcript expression observed for ASPN, CTSK, FBLN
and ZEB1, but there was no apparent increase for FN,
OGN and PARVA. Similarly, decreased stromal ex-
pression in prostate cancer was not apparent for CAV1,
CFH, NKTR, S100A6 and STC1, though the immuno-
localization data are not quantitative and are correlative
in comparison with the QrtPCR data (Figure 3). ASPN,
NKTR, S100A6 and ZEB1 expression was also ob-
served in epithelial cells; NKTR is a peripheral
membrane protein, ASPN appeared to be nuclear, and
both S100A6 and ZEB1 have been reported to be
expressed in epithelia. The expression of stromal
markers in epithelial cells might suggest a role in
EMT, and thus further colocalization experiments were
performed. Similarly, there appeared to be expression of
ASPN and STC1 in localized areas of stroma associated
with tumour epithelia, and these stromal markers were
examined for evidence of co-expression in stromal
subsets.
Colocalization of identiﬁed candidates with E-cadherin to
determine co-expression of stromal markers in tumour
epithelia
We performed confocal colocalization studies with
ASPN, NKTR, S100A6 and E-cadherin to determine
whether the stromally expressed molecules were also
expressed in epithelia (Figures 7a–c). ASPN, NKTR and
Figure 4 Distribution of identiﬁed candidate proteins in fetal
human prostate. Samples are orientated with the posterior at the top
and the anterior at the bottom, UR denotes urethra, SV denotes
seminal vesicles, and selected prostatic ducts are highlighted with
arrows in (a, b). The scale bar represents 500mm. (a–m) Low-
magniﬁcation images: expression of ASPN, FBLN, PARVA, ZEB1,
CAV1, CFH, NKTR and STC1 was observed in a subset of
prostatic mesenchyme; and ASPN, FBLN, PARVA, CAV1 and
NKTR showed enrichment in prostatic mesenchyme at the
periphery of the organ where epithelial branching morphogenesis
is concentrated. Expression of CTSK and S100A6 was highly
restricted to a small subset of cells in the mesenchyme, while OGN
was broadly expressed throughout the mesenchyme. (n–y) High-
magniﬁcation images: mesenchyme-speciﬁc staining for CTSK,
FBLN, FN, OGN, PARVA, CAV1, S100A6 and STC1. There
was some evidence of nuclear staining in epithelia for ASPN, while
ZEB1, CFH, NKTR and STC1 showed limited expression in a
subset of epithelia. Scale bar is 50mm, E, epithelia; M, mesenchyme.
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cancer. (a–m) Low-magniﬁcation images (scale bar is 200mm):
all molecules showed stromal expression and ASPN, PARVA,
CAV1, S100A6 and STC1 showed a localization to discrete areas of
stroma and stromal subsets, while CTSK, FN, OGN, ZEB1 and
CFH showed expression throughout the stroma. ASPN and STC1
showed staining in localized stromal areas containing tumour
epithelia. (n–y) High-magniﬁcation images (scale bar is 50mm):
this conﬁrmed that all candidates showed stromal staining,
and also identiﬁed some epithelial staining for ASPN, ZEB1,
NKTR and S100A6. Nuclear staining in epithelia was observed
for ASPN and NKTR, while S100A6 was observed in some
epithelia. Prostate cancer tissue was conﬁrmed as tumour tissue
by absence of epithelial microseminoprotein, beta (MSMB)
expression (Supplementary Figure 5).
Figure 5 Distribution of identiﬁed candidate proteins in benign
prostate. Low-magniﬁcation images (a–m) showed that there was
little expression of ASPN, CTSK, FBLN, ZEB1 and STC1 in the
stroma, and was limited to few cells or small areas. FN, OGN,
PARVA, CAV1 and S100A6 showed broad staining throughout
the stroma (scale bar is 200mm). High-magniﬁcation images (n–y)
showed that FN, OGN, PARVA, CAV1 and CFH were robustly
expressed in most stromal cells, while CTSK, FBLN, NKTR and
STC1 were expressed in a small subset of the stroma. (n–y) High-
magniﬁcation images: most candidates showed stromal expression,
CTSK, FBLN, ZEB1, NKTR and STC1, were expressed in few
cells and stromal subsets, while FN, OGN, PARVA, CAV1, CFH
and S100A6 showed robust stromal staining. ASPN showed some
nuclear staining in epithelia, and NKTR showed some surface
staining of epithelia (scale bar is 50mm). Benign prostate was
obtained from patients undergoing transurethral resection of the
prostate, and was conﬁrmed as non-tumour using microsemino-
protein, beta (MSMB) staining (Supplementary Figure 5).
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colocalization with E-cadherin, though in only a small
proportion of epithelia. This suggested that they might
be markers of EMT, and we performed further
colocalization of ASPN, NKTR and S100A6 with both
PanCK and ZEB1. PanCK was chosen as our epithelial
marker to conﬁrm the epithelial colocalization observed
with E-cadherin, while ZEB1 has been shown to mark
some EMT cells. We observed colocalization of ASPN,
NKTR and S100A6 with ZEB1; however, there was
little or no colocalization with PanCK-positive epithelia.
To examine whether ASPN and STC1 were expressed in
distinct and/or overlapping stromal areas, we performed
colocalization studies with these and PanCK. The data
showed that there were stromal areas, which expressed
either ASPN or STC1 individually, and there were
other areas of co-expression. These areas lacked
PanCK expression and thus were stromal rather than
epithelial.
Discussion
Mesenchyme and stroma have a key role in regulating
prostate development and growth, while CAFs in
tumour stroma control tumour progression via potent
paracrine acting pathways and other mechanisms
(Cunha et al., 2002; Bhowmick et al., 2004). We have
applied Tag proﬁling to human CAF, NPF and fetal
prostate to identify molecules expressed in prostatic
stroma, and focused upon secreted or surface bound
molecules present in development and disease. A
requirement for a stromal paracrine acting regulator of
epithelia is that it is secreted or surface bound, and such
molecules would be good therapeutic targets due to their
availability and mechanism of action. Our data showed
signiﬁcant overlap with existing data on tumour stroma
(Dakhova et al., 2009; Madar et al., 2009; Pascal et al.,
2009; Gregg et al., 2010) as well as identifying molecules
not previously known to be expressed in mesenchyme
Figure 7 Colocalization of identiﬁed candidates to determine co-expression with epithelial and stromal markers. To examine whether
ASPN, NKTR and S100A6 were co-expressed in both stroma and a subset of epithelia, we used confocal colocalization with
E-cadherin. (a–c) Overlap between all three molecules and E-cadherin (highlighted by white arrows), in addition to expression in the
stroma is shown. Further colocalization of ASPN, NKTR and S100A6 with both ZEB1 and PanCK was performed to conﬁrm the
E-cadherin results and to determine whether there was co-expression with ZEB1 in both stroma and epithelia. Stromal colocalization
was observed, and there was limited evidence of epithelial colocalization (d–f, white arrows), S100A6 was present in rare basal epithelia
as previously observed. To determine whether areas of stroma showed co-expression of ASPN and STC1, these were colocalized (in
addition to PanCK to distinguish epithelia (g, h)). There were areas of independent ASPN and STC1 expression (marked with green
and red asterisks) as well as areas of co-expression (marked by yellow asterisk).
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in the cellular composition and differentiation of
tumour stroma, and this variability is reﬂected in
transcript proﬁling data presented here and previously
published. CAFs and NPFs are grown as primary
cultures of ﬁbroblasts, and their composition is likely
to be less heterogeneous than tumour stroma in vivo.
The heterogeneity of tumour stroma and CAFs is a key
element of their pro-tumourigenic activity (Franco et al.,
2011; Kiskowski et al., 2011).
We note that there was most overlap of transcript
expression between CAFs and fetal prostate (Figure 1a),
and that developmental branching morphogenesis was
the top-identiﬁed process in CAFs (Figure 2), suggesting
strong similarity in pathways expressed in development
and disease (Joesting et al., 2005). Such similarities
have been noted in proﬁling studies of whole prostate
tumour tissue and developing prostate that focused
upon molecules and pathways in tumour epithelia
(Schaeffer et al., 2008; Pritchard et al., 2009).
Examination of candidate molecule mRNA levels in
paired CAF/NPF samples by QrtPCR showed signiﬁ-
cant variability between patients (Figure 3; Supplemen-
tary Table 1); however, there was general correlation
between the Tag library levels and those measured
in additional CAF/NPF pairs. We note that there seem
to be very few stromal molecules that show uniform
increase or decrease in CAFs, for example, CXCL12 or
WFDC1. Other data sets support the expression of our
identiﬁed candidates in prostate stroma (Dakhova et al.,
2009; Madar et al., 2009; Pascal et al., 2009; Gregg et al.,
2010). The changes in transcript levels that we observed
in the Tag libraries and by QrtPCR were supported by
the immunohistochemical protein localization, although
immunohistochemistry is not quantitative and was
performed to establish the tissue localization of candi-
date proteins rather than their levels. We suggest that
the high degree of variability in candidate expression
levels in CAFs is partly due to the heterogeneity of CAF
cellular composition; there are no reliable markers that
uniformly identify CAFs although some of the mole-
cules described here may be useful as markers if further
validated. In general, there appears to be a lack of
molecules whose expression is restricted to either stroma
or CAFs in comparison with numerous molecules
expressed in epithelia or both compartments. The
identiﬁcation of molecules expressed only in the stroma
or mesenchyme is a prerequisite for deﬁning new EMT
markers, and we noted expression of ASPN, NKTR and
S100A6 in stroma and epithelia, with evidence of some
colocalization with the ZEB1 EMT marker. Further
study of these candidates in EMT might be worthwhile.
In addition, we noted that ASPN and STC1 marked
restricted areas of stroma adjacent to tumour epithelia,
and that they showed both distinct and overlapping
expression patterns (Figure 7). It is possible that ASPN
and STC1 are molecular markers that can be used to
identify reactive stroma using immunohistochemistry,
though this will require follow-up in large patient
cohorts. Reactive stroma is currently deﬁned histologi-
cally using Massons trichrome staining, and molecular
markers of reactive stroma might be of use for
diagnostic purposes given the predictive power of
stromal histology (Ayala et al., 2003; Yanagisawa
et al., 2007).
Several of molecules that we have identiﬁed as
expressed in fetal prostate mesenchyme and CAFs have
been described in cancer stroma of breast, prostate and
other tumours. ASPN is a leucine rich proteoglycan
family member that is expressed in breast cancer-
associated stroma (Ma et al., 2009), which appears
to show some androgen dependence in prostate cancer
(Schaeffer et al., 2008) and which binds to TGFb
(Kizawa et al., 2005). CAV1 is downregulated in breast
and prostate CAFs and predicts early tumour recurrence
and poor outcome (Di Vizio et al., 2009; Witkiewicz
et al., 2009). S100A6 is an S100 calcium binding protein
family member that is upregulated in many tumours
(Lesniak et al., 2009), but is downregulated in prostate
cancer via promoter hypermethylation (Rehman et al.,
2005). STC1 is pro-survival factor in differentiated cells
with variable expression in tumours, which is also
involved in developmental mesenchymal–epithelial sig-
nalling (Stasko and Wagner, 2001; Joensuu et al., 2008).
We suggest that the co-expression of stromal pathways
in both mesenchyme and CAFs reﬂects the similarities
between developmental and tumour microenvironment;
however, the cellular complexity of the tumour micro-
environment may mean that further molecules remain to
be identiﬁed. The identiﬁcation of molecules expressed
in stromal subsets within the developing fetal prostate is
of relevance for understanding potential involvement in
CAF identity and pro-tumourigenic signalling because
during prostate development there are well-deﬁned
subsets of mesenchyme that contain organ-inductive
activity which regulates epithelial outgrowth and orga-
nogenesis (Timms et al., 1995). The identiﬁcation of
molecules expressed in these key subsets will deﬁne
markers of these regulatory cell populations as well
as paracrine regulators of epithelia made in these cell
subgroups (Vanpoucke et al., 2007). Thus, the expres-
sion patterns of ASPN, CAV1 and STC1 in restricted
areas of developmental prostatic mesenchyme are of
particular interest, especially given the restricted expres-
sion patterns of ASPN and STC1 in localized areas of
tumour stroma and potential as EMT markers. This
may indicate that these cell subsets express important
regulators of epithelia. We propose that our studies
have identiﬁed molecules showing stromal restricted
expression, some of which are expressed in stromal
subsets. These may be used to further characterize the
tumour microenvironment and elucidate the cellular
heterogeneity.
Materials and methods
Tag proﬁling
RNA from a patient-matched pair of CAF and NPF cells
and pooled embryonic prostate tissue were submitted for
Tag proﬁling by Solexa/Illumina (San Diego, CA, USA)
technology (http://www.Illumina.com). Brieﬂy, mRNA was
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scribed.
DpnII and MmeI were used as the anchoring and tagging
restriction enzymes, respectively. Sequencing was carried
out using the Illumina Genome Analyzer. The Illumina tag
proﬁling protocol identiﬁes mRNA transcripts by their unique,
positionally known 20 base pair cDNA tag.
Data analysis
Tag proﬁling data were received from Solexa in the form of tab
delimited text ﬁles that listed DNA sequences (20 mer) and the
counts for individual sequences, which were mapped against
the Human Genome (Unigene: HG201). Annotation of the
cDNA signature was classed according to their position
relative to the polyadenylation signal and the orientation
relative to the source mRNA. Signatures classiﬁed as classes 1,
2 or 3 were identiﬁed as oriented to the forward strand and/or
as the 30 most sequence close to a polyA signal or polyA tail.
The frequency of signature expression was converted to
transcripts per million (tpm) and signatures that were present
at a frequency of more than three tpm were selected for further
analysis. To determine shared and unique expression, the data
sets were compared using the signature sequence Microsoft
Access. Statistical comparison of gene expression in the full
CAF and NPF data sets was performed using JumpStart
software (IBM) http://domino.watson.ibm.com/comm/research_
projects.nsf/pages/jumpstart.index.html (Stolovitzky et al., 2005).
A 95% conﬁdence interval was applied. The assignment of
molecular function was performed using GeneGO software
(http://www.GeneGo.com).
Analysis of prostate cancer microarray expression data
We obtained expression proﬁle data sets of CD90þve and
CD49aþve prostate stroma from Pascal et al., (2009) (GEO
accession GSE17906) and patient-matched reactive stroma and
normal stroma of the prostate from Dakhova et al. (2009)
(GEO accession GSE11682—batch corrected data). Raw data
values were unlogged and averaged for similar samples. Fold
difference in gene expression was calculated for CD90þve vs
CD49aþve prostate stroma and normal stroma vs reactive
stroma. A threshold of X1.25 fold was selected as the cutoff
for differential gene expression in analysis of each data set.
Data points were removed for poorly annotated genes with
only a sequence identiﬁer or without a gene symbol.
Comparison of our CAF/NPF tag proﬁling data sets
(Po0.05) with these published microarray data was performed
using Microsoft Access using the gene symbol to ﬁlter for
unique and shared gene expression.
Tissue collection
Human fetal prostate tissue was obtained following medical
termination of pregnancy. Consent was obtained in accor-
dance with UK guidelines and the study was approved by the
Lothian Research Ethics Committee (08/S1101/1). The bladder
and urethra were excised, and the prostate microdissected
before RNA isolation. Human adult prostate tissue was
obtained from patients undergoing surgery (transurethral
resection of the prostate at the Western General Hospital,
Edinburgh). Patient consent was obtained before surgery and
the study was approved by ethical review (MREC 02/5/63).
Isolation and culture of primary human cells
Matched pairs of CAFs and NPFs were prepared from human
prostate tumours as described previously (Olumi et al.,
1999).Brieﬂy, benign tissue and tumours were identiﬁed using
histopathological analysis of stained frozen sections. Five mm
3
of tissue fragments immediately adjacent to identiﬁed normal
tissue and carcinoma was used. Specimens were digested with
collagenase and hyaluronidase and placed into culture in
RPMI-1640 containing penicillin, streptomycin and Fungizone
supplemented with 10% fetal bovine serum. After 10 days of
growth, the ﬁbroblastic cells were separated from contaminat-
ing epithelial and endothelial cells by differential trypsiniza-
tion. Subsequent immunocytochemical characterization
conﬁrmed their ﬁbroblastic nature. Following outgrowth of
stromal cells, the primary cultures were passaged, and the NPF
or CAF phenotype was validated according to their tumouri-
genic activity in tumour reconstitution assays.
RNA extraction and quantitative RT–PCR
Total RNA was extracted using the RNeasy Mini (Qiagen,
Crawley, UK) as per the manufacturer’s instructions and RNA
concentration and purity was measured on the Agilent 2100
Bioanalyser (Agilent Biotechnologies, Santa Clara, CA, USA).
Quantitative PCRs were performed on ABI 7500 machine,
using the PowerSybr PCR mastermix (ABI, Warrington, UK).
Transcript abundance was normalized to TBP expression. The
PCR primer sequences are provided below.
Primer sequences used for qRT–PCR
Immunohistochemistry
The histology of sections was examined by haematoxylin staining
(H&E). For immunostaining, sections were pressure cooked in
10mM citric acid, pH 6.0, for 5min. Sections to be stained with
30 3-diaminobenzidine (DAB) were treated following a Human
Protein Atlas modiﬁed protocol (http://www.proteinatlas.org)
using the Immpress peroxidase kit (Vector Laboratories, Burlin-
game, CA, USA) and species appropriate secondary labelled
polymer. Antibody concentrations are listed below. Colocaliza-
tions were performed with ECAD (BD Biosciences, Oxford, UK)
diluted 1:1000 or PCK (Sigma-Aldrich Company Ltd, Dorset,
UK) diluted 1:4000 and ZEB1 (Sigma-Aldrich Company, Ltd,
Poole, UK) diluted 1:1000. ASPN, NKTR (Sigma) and S100A6
(Thermo Fisher Scientiﬁc, Rockford, IL, USA) were diluted 1:50.
Antibodies were visualized with species appropriate peroxidase
secondary and Tyramide (Perkin-Elmer, Boston, MA, USA)
(Zeb1) or species appropriate conjugated avidin-alexaﬂuor 488,
546 or 633 (Molecular Probes Inc., Eugene, OR, USA). Sections
were counterstained with DAPI (Sigma-Aldrich Company Ltd) or
T O P R O( M o l e c u l a rP r o b e sI n c . ) .I m a g e sw e r ec a p t u r e du s i n ga
Provis microscope (Olympus Optical Co., London, UK) equipped
with a DCS330 camera (Eastman Kodak Co., Rochester, NY,
USA). Confocal microscopy was performed on a Zeiss LSM 510
Laser scanning microscope (Carl Zeiss Microimaging Inc.,
Thornwood, NY, USA).
Gene Forward Reverse
ASPN AAGAACTACCAAAGGCTGGC CTCTGGTAATCCTGAAGGGA
CTSK GGATCCAGAAGGGAAACAAGC TGGCTGGAGTCACATCTTGG
FBLN1 TGCGAATGCAAGACGG CGTAGACGTTGGCACA
FN GGAAGTTGTTGCTGCGACCC GCCGCTGATGGTAGCTGTAG
OGN GTTGACATTGATGCTGTACCACCC GCTTGGGAGGAAGAACTGGA
PARVA TCCGGGAGGCATGAACGTGA AGCTGTGCAGGGGCACAAAGT
ZEB1 GCACCTGAAGAGGACCAGAG TGCATCTGGTGTTCCATTTT
CAV1 ACAGCCCAGGGAAACCTCCT CGGATGGGAACGGTGTAGAG
CFH AAGGCGGGTGAGCAAGTGAC TGGGCGGATTCACACAGGAGGT
NKTR CTCAAACATGACAGAGCGTTCC AAAGAGAGAGAGAGCCTTAGAG
S100A6 CTCACCATTGGCTCGAAGCT AGTCTTCCATCAGCCTTGCAA
STC1 CACACCCACGAGCTGACTTC TCTCCCTGGTTATGCACTCTCA
DCN GCCAACACGCCTCATCTGAG TGTCCAGGTGGGCAGAAGTC
FHL1 GACTGGAAGCTTCTTCCCTAAAG CCAGCTTCTTAGAGCAGGTAACA
SPARC AGTACATCGCCCTGGATGAG CCGGTACTGTGGAAGGAGTG
CXCL12 AGAGCCAACGTCAAGCATC CTTTAGCTTCGGGTCAAGCT
WFDC1 GGCGAATCCTACGACACAAAC TCTTGCAACCTAGCTGCTTGC
SMACT TGTAAGGCCGGCTTTGCT CGTAGCTGTCTTTTTGTCCCATT
TBP AGGTTAGAAGGCCTTGTGCTC GGGAGGCAAGGGTACATGAG
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